1. Safety of administration of BNT162b2 mRNA (Pfizer‐BioNTech) COVID‐19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG‐asparaginase
- Author
-
Catherine Mark, Alice Heisey, Christine McGovern, Angela Punnett, Adelle Atkinson, Sarah Alexander, Sumit Gupta, Julia Orkin, Lindsay Clarke, and Julia Upton
- Subjects
Adult ,Allergy ,medicine.medical_specialty ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,Lymphoblastic Leukemia ,Antineoplastic Agents ,PEG‐asparaginase ,Polyethylene Glycols ,Drug Hypersensitivity ,Young Adult ,Internal medicine ,vaccine ,Medicine ,Asparaginase ,Humans ,Young adult ,Child ,BNT162 Vaccine ,Oncology: Brief Report ,COVID ,PEG-asparaginase ,business.industry ,technology, industry, and agriculture ,COVID-19 ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,allergy ,Vaccination ,Oncology ,El Niño ,Pediatrics, Perinatology and Child Health ,Cohort ,business - Abstract
Vaccinationis a critical tool in the prevention of COVID‐19 infection for individuals and for communities. The mRNA vaccines contain polyethylene glycol (PEG) as a stabilizer. Currently, in North America, only the BNT162b2 (Pfizer‐BioNTech) mRNA vaccine is approved for individuals aged 12–17. Most patients treated with contemporary regimens for acute lymphoblastic leukemia receive PEG‐asparaginase (PEG‐ASNase) and 10%–30% will develop allergic reactions. Optimizing access and safety for vaccine administration for these patients is critical. This report describes a process developed to support COVID vaccination in a cohort of adolescents and young adults with a history of PEG‐ASNase allergy.
- Published
- 2021